BRPI0820388A2 - Molécula concatenada para a modulação da atividade do sistema imunológico humano e animal, composição, kit, fármaco e uso - Google Patents

Molécula concatenada para a modulação da atividade do sistema imunológico humano e animal, composição, kit, fármaco e uso

Info

Publication number
BRPI0820388A2
BRPI0820388A2 BRPI0820388-1A2A BRPI0820388A BRPI0820388A2 BR PI0820388 A2 BRPI0820388 A2 BR PI0820388A2 BR PI0820388 A BRPI0820388 A BR PI0820388A BR PI0820388 A2 BRPI0820388 A2 BR PI0820388A2
Authority
BR
Brazil
Prior art keywords
modulating
kit
drug
activity
human
Prior art date
Application number
BRPI0820388-1A2A
Other languages
English (en)
Inventor
Matthias Schroff
Burghardt Wittig
Manuel Schmidt
Janine Loehr
Christiane Kleuss
Original Assignee
Mologen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mologen Ag filed Critical Mologen Ag
Publication of BRPI0820388A2 publication Critical patent/BRPI0820388A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
BRPI0820388-1A2A 2007-11-07 2008-11-07 Molécula concatenada para a modulação da atividade do sistema imunológico humano e animal, composição, kit, fármaco e uso BRPI0820388A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07075967A EP2058397A1 (de) 2007-11-07 2007-11-07 Multimeres Assemblat zur Immunstimulation
PCT/EP2008/009618 WO2009059805A1 (de) 2007-11-07 2008-11-07 Catenate zur immunstimulation

Publications (1)

Publication Number Publication Date
BRPI0820388A2 true BRPI0820388A2 (pt) 2014-10-14

Family

ID=38990155

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820388-1A2A BRPI0820388A2 (pt) 2007-11-07 2008-11-07 Molécula concatenada para a modulação da atividade do sistema imunológico humano e animal, composição, kit, fármaco e uso

Country Status (13)

Country Link
US (1) US20100303803A1 (pt)
EP (2) EP2058397A1 (pt)
JP (1) JP2011502492A (pt)
KR (1) KR20100087359A (pt)
CN (1) CN101883854A (pt)
AU (1) AU2008324384A1 (pt)
BR (1) BRPI0820388A2 (pt)
CA (1) CA2703983A1 (pt)
EA (1) EA201000769A1 (pt)
IL (1) IL205543A0 (pt)
MX (1) MX2010004998A (pt)
TW (1) TW200927148A (pt)
WO (1) WO2009059805A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246433A1 (de) * 2009-04-30 2010-11-03 Mologen AG Concatemere zur Immunmodulation
US20130245102A1 (en) * 2010-10-12 2013-09-19 Research Foundation Of The City University Of New York Novel dna templates for small rna production in mammalian cells
KR102290205B1 (ko) 2014-06-04 2021-08-20 엑시큐어, 인크. 예방 또는 치료 용도를 위한 리포솜성 구형 핵산에 의한 면역 조절인자의 다가 전달
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19935756A1 (de) * 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
CN1918293A (zh) * 2004-02-20 2007-02-21 莫洛根股份公司 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子
WO2006015560A1 (de) * 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
PT2027266E (pt) * 2006-05-11 2011-03-14 Mologen Ag Multímero para a imunoestimulação

Also Published As

Publication number Publication date
AU2008324384A1 (en) 2009-05-14
JP2011502492A (ja) 2011-01-27
TW200927148A (en) 2009-07-01
EP2058397A1 (de) 2009-05-13
IL205543A0 (en) 2010-12-30
WO2009059805A1 (de) 2009-05-14
KR20100087359A (ko) 2010-08-04
EA201000769A1 (ru) 2010-12-30
MX2010004998A (es) 2010-08-02
CA2703983A1 (en) 2009-05-14
CN101883854A (zh) 2010-11-10
EP2207880A1 (de) 2010-07-21
US20100303803A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
MA28489B1 (fr) Preparations pharmaceutiques
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BRPI0923500A2 (pt) uso e composição farmacêutica compreendendo agonista ou modulador do receptor s1p, e kit.
BRPI0822121A2 (pt) Composição para cuidado oral, e uso da mesma
BRPI0912356A2 (pt) compostos moduladores de sirtuína, composição farmacêutica compreendendo os mesmos e seu uso
BR112013016772A2 (pt) composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI0916829A2 (pt) axmi-115, axmi-113, axmi-005, axmi-13 e axmi-184; proteínas inseticidas e metódos para seu uso.
BRPI0811436A2 (pt) Composto, uso de um composto, composição farmacêutica, e, metódos para a terapia da dor em um animal de sangue quente, para a terapia da bexiga super ativa em um animal de sangue quente, e para preparar um composto.
BRPI0811865A2 (pt) Derivados heterocíclicos pirrolo-nitrogenados, a preparação e o uso farmacêutico dos mesmos
BRPI0820388A2 (pt) Molécula concatenada para a modulação da atividade do sistema imunológico humano e animal, composição, kit, fármaco e uso
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0914863A2 (pt) formulação tópica estável, e, uso da mesma
BRPI0813897A2 (pt) Uso de uma substância, composição cosmética ou dermo-cosmética ou neutracêutica, composição farmacêutica, método de cuidado cosmético, e, seqüência de nucleotídeos.
BRPI1010621A2 (pt) derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
DK2051975T3 (da) Substituerede prolinamider, fremstilling deraf og anvendelse deraf som lægemiddel.
BRPI0907572A2 (pt) Derivados de fluorglicosídeos aromáticos, fármacos compreendendo os referidos compostos e uso dos mesmos
BRPI0915552A2 (pt) derivados de ciclosporina, seu uso e sua composição farmacêutica
BRPI0821915A2 (pt) Piridil-n-(1,3,4)-tiadiazol-2-il-benzeno sulfonamidas cíclicas, processos para sua preparação e seu uso como produtos farmacêuticos
BRPI0907892A2 (pt) Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
BRPI0919794A2 (pt) dispositivo para uso intracorpóreo, e, composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A, 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]